NCT05242887

Brief Summary

Delirium is very common in hospitalized older patients and associated with serious clinical bad outcomes (e.g. increased risk of functional decline and death). Despite its high prevalence in the hospital setting, delirium remains underdiagnosed. A better identification would allow an early management and a reduction of its complications. The validation of easy-to-use and quick and formalized tools for the identification of delirium and their implementation in the clinical practice are necessary. Recently, the 3D-CAM (3-minutes Diagnostic interview for Confusion Assessment Method -defined delirium) and the UB-CAM (Ultra-Brief CAM) showed very high sensitivity and specificity (\> 90%), compared to the reference standard (Diagnostic and Statistical Manual of Mental Disorders (DSM criteria)) for the diagnosis of delirium. The investigators aimed to evaluate the sensitivity and specificity of the French versions of the 3D-CAM and the UB-CAM used in delirium screening in older adults hospitalized in geriatric units, compared to reference standard.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
80

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 7, 2022

Completed
9 days until next milestone

First Posted

Study publicly available on registry

February 16, 2022

Completed
1 month until next milestone

Study Start

First participant enrolled

March 31, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 27, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 27, 2024

Completed
Last Updated

April 4, 2024

Status Verified

April 1, 2024

Enrollment Period

2 years

First QC Date

February 7, 2022

Last Update Submit

April 3, 2024

Conditions

Keywords

DeliriumCAMUB-CAM3D-CAM

Outcome Measures

Primary Outcomes (1)

  • Evaluation of the performance of a rapid diagnostic tool (UB-CAM) for acute confusional state, translated into French

    Presence or absence of a confusional state (with UB-CAM and the gold standard: DSM-V criteria)

    At inclusion

Secondary Outcomes (2)

  • Evaluation of the time taken to use this tool

    At inclusion

  • Evaluation of the diagnostic performance of another diagnostic tool (3D-CAM), already translated into French

    At inclusion

Study Arms (1)

Older adults hospitalized in acute geriatric units

Response to a questionnaire

Diagnostic Test: Delirium screening using 3D-CAM and UB-CAM

Interventions

Patients will be evaluated with 3D-CAM and UB-CAM by a trained examiner (geriatrician, resident or neuropsychologist). On the same day, they will be given a reference diagnosis of delirium based on DSM-V criteria by another trained examiner, blind to the results of the UB-CAM and 3D-CAM.

Older adults hospitalized in acute geriatric units

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)
Sampling MethodProbability Sample
Study Population

Older adults hospitalized in acute geriatric units

You may qualify if:

  • Adults hospitalized in acute geriatric units
  • Aged 65 or older
  • Patient (or relative) not objecting to participating in the study

You may not qualify if:

  • \- Legal protection regimes (guardianship, curatorship)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hôpital des Charpennes, Institut du Vieillissement, Hospices Civils de Lyon

Villeurbanne, Lyon, 69100, France

Location

MeSH Terms

Conditions

Delirium

Condition Hierarchy (Ancestors)

ConfusionNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsNeurocognitive DisordersMental Disorders

Study Officials

  • Antoine GARNIER-CRUSSARD, MD, MSc

    Hospices Civils de Lyon

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 7, 2022

First Posted

February 16, 2022

Study Start

March 31, 2022

Primary Completion

March 27, 2024

Study Completion

March 27, 2024

Last Updated

April 4, 2024

Record last verified: 2024-04

Data Sharing

IPD Sharing
Will not share

Locations